Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer

Press Release
 

Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer

Hennigsdorf/Berlin (Germany), February 1, 2023 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Stephan Witte as Chief Medical Officer (CMO) of Adrenomed. Dr. Stephan Witte is a drug development professional with over 20 years of experience in clinical development and a strong disease expertise in sepsis and septic shock.

“I am delighted to welcome Stephan to the Adrenomed team. Stephan has profound knowledge in all phases of clinical development and successfully designed and implemented global development programs. He is truly a drug development expert, and we will strongly benefit from his expertise in sepsis and septic shock as well as other relevant therapeutic indications,” commented Dr. Richard Jones, CEO of Adrenomed.

Dr. Stephan Witte, CMO of Adrenomed, added: “I am intrigued by the opportunity of bringing an innovative treatment against septic shock closer to market to fill the medical need in this very serious condition with a high death toll. Adrenomed provides excellent prerequisites for reaching this ambitious goal: a smart biomarker-guided therapeutic approach, backed by a strong scientific knowledge base and a leadership team which is strongly dedicated to fighting sepsis. I look forward to working with an experienced team to deliver a treatment option that could change the standard of care in this indication.”

Before joining Adrenomed, Stephan Witte, Ph.D., was Vice President Clinical Science & Operations at Atriva Therapeutics, a clinical-stage biotech company focusing on antiviral therapeutics. Prior to that, he was Vice President Clinical Trials at Breath Therapeutics and Head of Clinical Development and Regulatory Affairs at Inotrem, a biotech company specializing in inflammatory syndromes. Here, Stephan Witte was responsible for the clinical development and regulatory interactions for Inotrem’s lead compound in the indication of septic shock. Furthermore, he designed, optimized, and implemented global drug development projects for several biotech and pharma companies as founder and owner of Helion Pharma, a drug development and registration consultancy.

Stephan Witte holds a diploma (M.A. equivalent) in Chemistry and a Ph.D. in Biochemistry and Immunology from University of Konstanz, Germany. He completed Advanced Studies in Pharmaceutical Medicine at the European Center of Pharmaceutical Medicine (ECPM) in Basel, Switzerland.

About Adrenomed

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab (INN: enibarcimab) is a first-in-class non-blocking monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.

Contact
Adrenomed AG
Martina Kalle-Brune, Ph.D.
phone: +49 (0)3302 207780
bd@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 2102280
adrenomed@mc-services.eu

For a high-resolution image, please contact adrenomed@mc-services.eu.